HealthFusion's MediTouch® EHR Ranked as Top 3 for Clinical Quality and Support in Medical Economics' National Provider Survey

SOLANA BEACH, Calif., Oct. 2014 /PRNewswire/ -- HealthFusion, maker of MediTouch EHR, the leading cloud computing software for physicians, hospitals, and medical billing services, was ranked as a Top 3 Electronic Health Record (EHR) for Clinical Quality and Support in the Medical Economics' National Provider Survey. Of those Top 3 EHRs, MediTouch is unique because it is the only one to offer full functionality on the Apple iPad. The Medical Economics National Provider Survey is a critical EHR ranking study because it asked thousands of physicians to rate their systems, on a scale of 0 to 10, in the key areas that matter most to them.

MediTouch EHR is an important solution for managing the chronically ill, optimizing the health of populations, and in the process, right-sizing healthcare spending such that medical care becomes more affordable. The program utilizes tablet devices such as the Apple iPad and smartphone touchscreen interface, as well as cross-compatibility with traditional desktop and laptop devices.

"We are thrilled to be ranked among the best EHRs by Medical Economics, because that ranking reflects the satisfaction of our most important constituent, the physician." said Dr. Seth Flam, CEO of HealthFusion. "As a physician I understand how challenging the practice of medicine can be, therefore we remain dedicated to continue improving our EHR and medical billing software to help physicians nationwide provide the best possible care for their patients."

According to Medical Economics, "The performance of an EHR system can mean the difference between a thriving practice and a struggling one. These systems impact every aspect of medical care, from the care physicians provide to patients to the practice's ability to get paid for the work it does."

In addition to the top 3 ranking in the Clinical Quality of Care and Support areas, MediTouch was also well-ranked in the categories of Patient Portal and Technical Support and Meaningful Use —both of which contribute overall customer satisfaction of utilizing the solution. MediTouch is the only EHR recognized by J.D. Power and Associates for Providing an Outstanding Customer Service Experience.

MediTouch EHR is one facet of HealthFusion's overall mission to better connect individuals, doctor's offices and hospitals with the goal of improving quality of care within the health industry. For more information about HealthFusion and its products, please visitwww.HealthFusion.com.

About HealthFusion: 
HealthFusion develops web-based, cloud computing software for physicians, hospital ambulatory centers, and medical billing services. Our fully integrated solution includes MediTouch EHR (Electronic Health Record), MediTouch PM (Practice Management and Claims Clearinghouse) and Patient Portal.

About MediTouch EHR: 
The MediTouch iPad native, cloud-based, all-in-one EHR software is easily customizable to suit the unique needs of any medical practice, and was one of the very first pure ambulatory EHRs on the market to receive Meaningful Use Stage 2 certification. MediTouch EHR utilizes an intuitive tablet and smartphone touchscreen interface, as well as cross-compatibility with traditional desktop and laptop devices (Windows or Mac). HealthFusion is dedicated to connecting healthcare industry participants in the United States to reduce administrative costs, offer a superior customer service experience, and improve the overall quality of healthcare. Thousands of users throughout the country place their trust in HealthFusion and MediTouch every day. www.HealthFusion.com

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.